In a report published Tuesday, Bank of America analyst Steve Byrne upgraded the rating on Seattle Genetics SGEN from Underperform to Neutral, but lowered the price target from $46.00 to $40.00.
In the report, Bank of America noted, “We rate SGEN shares Neutral. While we believe expectations for Adcetris' label expansions are mostly priced in, given the stock's pull-back and potential favorable AETHERA readout in 2H14 we rate SGEN shares Neutral. SGEN's ADC platform could add upside to valuation but these wholly owned products are in early stage development.”
Seattle Genetics closed on Monday at $35.10.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in